RecruitingPhase 1NCT04485559

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade Gliomas

Sponsor

University of California, San Francisco

Enrollment

50 participants

Start Date

Dec 9, 2020

Study Type

INTERVENTIONAL

Conditions

High Grade Glioma Low-grade Glioma Recurrent World Health Organization (WHO) Grade II Glioma

Summary

This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone.

Eligibility

Min Age: 1 YearMax Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Everolimus and a drug called Trametinib for people with high grade glioma, low-grade glioma, and other related conditions. The study is currently recruiting participants at 17 locations. People eligible for this study include aged 1 Year to 25 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEverolimus

Given PO

DRUGTrametinib

Given PO

Locations(17)

University of Alabama at Birmingham, Children's of Alabama

Birmingham, Alabama, United States

Children's Hospital Los Angeles

Los Angeles, California, United States

University of California, San Diego Rady Children's Hospital

San Diego, California, United States

University of California, San Francisco

San Francisco, California, United States

Children's National Medical Center

Washington D.C., District of Columbia, United States

University of Florida

Gainesville, Florida, United States

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Riley Hospital for Children

Indianapolis, Indiana, United States

John Hopkins University

Baltimore, Maryland, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Children's Minnesota

Minneapolis, Minnesota, United States

Washington University in St. Louis

St Louis, Missouri, United States

Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center

Hackensack, New Jersey, United States

New York University

New York, New York, United States

Doernbecher Children's Hospital Oregon Health & Science University

Portland, Oregon, United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

University Of Texas Southwestern Medical Center

Dallas, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04485559

Related Trials

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

NCT04166409132 locations

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

NCT052782084 locations

Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT074161881 location

A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Recurrent or Progressive High-grade Glioma

NCT077106903 locations

Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas

NCT039484901 location